MEDULLARY THYROID CANCER
Clinical trials for MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in slowing rare thyroid cancer
Disease control CompletedThis phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many pa…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New PET tracer could spot hidden thyroid cancer
Diagnosis CompletedThis study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…
Matched conditions: MEDULLARY THYROID CANCER
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
Thyroid cancer patients may spend less time in discomfort with simple phone calls
Symptom relief CompletedThis completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC